Top

Internal and Emergency Medicine

Published in:

01-11-2020 | Atorvastatin | CE-Research Letter to the Editor

Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action

Authors: Rosario Rossi, Marisa Talarico, Francesca Coppi, Giuseppe Boriani

Published in: Internal and Emergency Medicine | Issue 8/2020

Excerpt

Dear Editor, …

Zhang W, Zhao Y, Zhang F et al (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of immunologists from China. ClinImmunol. https://doi.org/10.1016/j.clim.2020.108393CrossRef

Schönbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as anti-inflammatory agents? Circulation 109:II-18–II-26CrossRef

Massachusetts General Hospital COVID-19 Treatment Guidance Version 1.0 3/17/2020. Available at: https://medtube.net/infectious-diseases/medical-documents/26086-covid19-treatment-guidelines-by-massachusetts-general-hospital. Accessed March 28, 2020.

Reiner Ž, Hatamipour M, Banach M et al (2020) Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 16(3):490–496CrossRefPubMedPubMedCentral

Stone NJ, Robinson J, Lichtenstein AH et al (2013) 2013 ACC AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adult: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am CollCardiol 63:2889–2934CrossRef

Wadman M, Couzin-Frankel J, Kaiser J, Matacic C (2020) How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Science. https://doi.org/10.1126/science.abc3208CrossRefPubMed

Perrella A, Trama U, Bernardi FF et al (2020) Editorial-COVID-19, more than a viral pneumonia. Eur Rev Med Pharmacol Sci 24(9):5183–5185PubMed

Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMANeurol 2020:e201127

Cinti S, Graciotti L, Giordano A, Valerio A, Nisoli E (2020) COVID-19 and fat embolism: a hypothesis to explain the severe clinical outcome in people with obesity. Int J Obes. https://doi.org/10.1038/s41366-020-0624-5CrossRef

10.

Rossi R, Coppi F, Talarico M, Boriani G (2020) Protective role of chronic tretment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Europ J Intern Med. https://doi.org/10.1016/j.ejim.2020.06.006CrossRef

11.

Karbalai Saleh S, Oraii A, Soleimani A et al (2020) The association between cardiac injury and outcomes in hospitalized patients with COVID-19. Intern Emerg Med. https://doi.org/10.1007/s11739-020-02466-1CrossRefPubMedPubMedCentral

12.

Fajgenbaum DC, Rader DJ (2020) Teaching old drugs new tricks: statins for covID-19? Cell Metab 32(2):145–147CrossRefPubMedPubMedCentral

13.

Zhang XJ, Qin JJ, Cheng X et al (2020) In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 32(2):176–187.e4CrossRefPubMedPubMedCentral

14.

Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G (2020) Statin therapy in COVID-19 infection. Eur Heart J CardiovascPharmacother. https://doi.org/10.1016/j.cmet.2020.06.015CrossRef

Title: Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action
Authors: Rosario Rossi
Marisa Talarico
Francesca Coppi
Giuseppe Boriani
Publication date: 01-11-2020
Publisher: Springer International Publishing
Keywords: Atorvastatin
Statins
COVID-19
Published in: Internal and Emergency Medicine / Issue 8/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02504-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2020

COVID-19, coagulopathy and venous thromboembolism: more questions than answers

Should the search for COVID-19 become part of the work-up of incidental thromboembolism? A near-missed COVID-19 diagnosis

The COVID-19 epidemic and reorganisation of triage, an observational study

How cardiologists respond to COVID-19: the experience of West China Hospital, China

COVID-19 pandemic and Internal Medicine Units in Italy: a precious effort on the front line

From the quarantine diary of an emergency physician: the coronavirus and the dysautonomic storm

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials